Gilteritinib Induces Differentiation in Relapsed and Refractory FLT3-mutated Acute Myeloid Leukemia.

Christine M McMahon,Jonathan Canaani,Bryan Rea,Rachel L Sargent,Julianne N Qualtieri,Christopher D Watt,Jennifer J D Morrissette,Martin Carroll,Alexander E Perl

Blood advances（2019）

引用 56|浏览45

暂无评分

摘要

Gilteritinib induces 2 distinct marrow responses in FLT3-mutated AML: responses with and without differentiation. Ongoing clonal hematopoiesis is ubiquitous during gilteritinib therapy and may promote genetic evolution and drug resistance.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要